Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD.

BMJ Open Gastroenterol · 2018 · PMC6001911 · PMID 29915667

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

a weak trendp=0.09so close (0.05 < p ≤ 0.1)

Additionally, a weak trend of higher plasma levels of soluble gp130 among responders was observed (median 17 630 pg/mL vs 15 719 pg/mL, p=0.09).

also in 1,404 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.